How big is CRISPR Therapeutics AG?

As of Jun 18, CRISPR Therapeutics AG has a market capitalization of 3,737.84 million, with net sales of 37.67 million and a net profit of -385.66 million over the latest four quarters. The company reported shareholder's funds of 1,932.08 million and total assets of 2,242.03 million as of Dec 24.

Market Cap: <BR>As of Jun 18, CRISPR Therapeutics AG has a market capitalization of 3,737.84 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, CRISPR Therapeutics AG reported net sales of 37.67 million and a net profit of -385.66 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company reported shareholder's funds of 1,932.08 million and total assets of 2,242.03 million.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a Switzerland-based gene-editing company focused on developing gene-based medicines for serious diseases. As of March 2025, it reported net sales of $1 million and a net loss of $136 million, with a market cap of approximately $3.74 billion.

Overview:<BR>CRISPR Therapeutics AG is a Switzerland-based gene-editing company in the Pharmaceuticals & Biotechnology industry, focused on developing transformative gene-based medicines for serious diseases.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -136 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,737.84 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -21.08% <BR>Price to Book: 2.04<BR><BR>Contact Details:<BR>Address: Baarerstrasse 14, ZUG ZUG: 6300 <BR>Tel: ['41 41 5613277'] <BR>Website: http://www.crisprtx.com/about-us/contact

Should I buy, sell or hold CRISPR Therapeutics AG?

Who are in the management team of CRISPR Therapeutics AG?

As of March 2022, the management team of CRISPR Therapeutics AG includes Dr. Rodger Novak (Chairman, President, Co-Founder) and Dr. Samarth Kulkarni (CEO, Director), along with independent directors Dr. Ali Behbahani, Dr. Bradley Bolzon, Dr. Simeon George, Mr. John Greene, and Dr. Katherine High.

As of March 2022, the management team of CRISPR Therapeutics AG includes the following individuals:<BR><BR>- Dr. Rodger Novak, who serves as the Chairman of the Board, President, and Co-Founder.<BR>- Dr. Samarth Kulkarni, who is the Chief Executive Officer and a Director.<BR><BR>Additionally, the Board of Directors includes several independent directors: Dr. Ali Behbahani, Dr. Bradley Bolzon, Dr. Simeon George, Mr. John Greene, and Dr. Katherine High.

Is CRISPR Therapeutics AG overvalued or undervalued?

As of August 8, 2022, CRISPR Therapeutics AG is considered overvalued with a risky valuation grade, highlighted by a negative P/E ratio of -13.27 and a negative ROE of -21.08%, despite a strong year-to-date stock return of 59.91%.

As of 8 August 2022, the valuation grade for CRISPR Therapeutics AG moved from fair to risky, indicating a shift towards a more negative outlook. The company is currently considered overvalued given its financial metrics, particularly with a Price to Book Value of 1.98 and a negative EV to EBIT of -3.76. Additionally, the Return on Equity (ROE) stands at -21.08%, further highlighting the challenges the company faces in generating returns for its shareholders.<BR><BR>In comparison to its peers, CRISPR Therapeutics AG's P/E ratio is notably negative at -13.27, while Illumina, Inc. and BioMarin Pharmaceutical, Inc. have fair valuations with P/E ratios of 19.09 and 15.17, respectively. This stark contrast underscores the difficulties CRISPR is experiencing relative to its industry. Despite a strong year-to-date stock return of 59.91%, which outperformed the S&P 500's 12.22%, the longer-term outlook remains concerning, as reflected in the negative returns over the 3-year and 5-year periods.

Is CRISPR Therapeutics AG technically bullish or bearish?

As of October 31, 2025, CRISPR Therapeutics AG shows a bullish technical trend, supported by positive MACD indicators and a strong year-to-date return of 43.32%, despite recent underperformance compared to the S&P 500 and mixed signals from other indicators.

As of 31 October 2025, the technical trend for CRISPR Therapeutics AG has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a positive outlook. While the Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames, the daily moving averages show a mildly bullish trend. However, the KST and Dow Theory present a mixed picture, with weekly signals being mildly bearish and monthly signals bullish. <BR><BR>The stock has underperformed the S&P 500 over the past week and month, with returns of -14.17% and -16.73% compared to the S&P 500's gains of 0.71% and 1.92%, respectively. Despite this recent underperformance, the year-to-date return of 43.32% significantly outpaces the S&P 500's 16.30%. Overall, the current technical stance is bullish, albeit with some caution due to mixed indicators.